Filtered By:
Specialty: Neurology
Drug: Pradaxa

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 127 results found since Jan 2013.

Ischemic Stroke in Patients with Elevated Body Mass Index while on Novel Anticoagulants: A case series report (P1.059)
CONCLUSIONS:We report and characterize the largest published case series of patients with non-valvular atrial fibrillation who had ischemic stroke while on novel oral anticoagulants. Elevated body mass index was noted among those who developed embolic strokes while on these agents.Disclosure: Dr. Kamal has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Mowla has nothing to disclose. Dr. Shirani has nothing to disclose. Dr. Sawyer has nothing to disclose. Dr. Fanous has nothing to disclose. Dr. Ching has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Kamal, H., Smith, K., Mowla, A., Shirani, P., Sawyer Jr., R., Fanous, A., Ching, M. Tags: Cerebrovascular Disease and Interventional Neurology: Atrial Fibrillation and Cardio-embolic Stroke Source Type: research

The Need for a Coagulation Assay after Initiation of New Oral Anticoagulants in Patients with Renal Dysfunction: A Case Report.
CONCLUSIONS: The present case emphasizes the need for frequent checking of renal function and assessment using coagulation assays after commencing dabigatran therapy in patients with moderate-to-severe renal impairment. PMID: 25749821 [PubMed - as supplied by publisher]
Source: Journal of Clinical Neurology - March 11, 2015 Category: Neurology Tags: J Clin Neurol Source Type: research

Letter by Feng et al Regarding Article, "Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control" Letters to the Editor
Source: Stroke - February 23, 2015 Category: Neurology Authors: Feng, X., Huan, Y., Lv, Y. Tags: Secondary prevention, Acute Cerebral Infarction Letters to the Editor Source Type: research

Response to Letter Regarding Article, "Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control" Letters to the Editor
Source: Stroke - February 23, 2015 Category: Neurology Authors: Chan, P.-H., Hai, J. J., Siu, C.-W. Tags: Coumarins Letters to the Editor Source Type: research

Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation
Opinion statement Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder, which can potentially increases the risk of stroke by five-fold, thus, resulting in high public healthcare burden. Stroke prevention is vital in the management of AF patients. Vitamin K antagonists (VKA, eg, warfarin) have been the mainstay treatment to prevent ischemic stroke and systemic thromboembolism in AF patients for several decades. Despite the efficacy of warfarin, its limitations have recently driven the advent of some new antithrombotic agents, the non-VKA oral anticoagulant (NOACs, including dabigatran, ri...
Source: Current Treatment Options in Neurology - February 11, 2015 Category: Neurology Source Type: research

Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients
ConclusionsWe report the largest series of cerebral vein thrombosis patients treated with dabigatran. Clinical outcome was excellent in most patients and not different from other studies. Dabigatran could possibly be considered an alternative to warfarin; nevertheless, further prospective assessment with randomized controlled studies is warranted.
Source: International Journal of Stroke - February 1, 2015 Category: Neurology Authors: Marcelo D. Mendonça, Raquel Barbosa, Vera Cruz‐e‐Silva, Sofia Calado, Miguel Viana‐Baptista Tags: Research Source Type: research

Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI‐NVAF Study
ConclusionsWarfarin use at acute hospital discharge was still common in the initial years after approval of nonvitamin K antagonist oral anticoagulants, although nonvitamin K antagonist oral anticoagulant users increased gradually. The index stroke was milder and ischemia‐risk indices were lower in nonvitamin K antagonist oral anticoagulant users than in warfarin users. Early initiation of nonvitamin K antagonist oral anticoagulants seemed safe.
Source: International Journal of Stroke - January 12, 2015 Category: Neurology Authors: Kazunori Toyoda, Shoji Arihiro, Kenichi Todo, Hiroshi Yamagami, Kazumi Kimura, Eisuke Furui, Tadashi Terasaki, Yoshiaki Shiokawa, Kenji Kamiyama, Shunya Takizawa, Satoshi Okuda, Yasushi Okada, Tomoaki Kameda, Yoshinari Nagakane, Yasuhiro Hasegawa, Hiroshi Tags: Research Source Type: research

Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control Clinical Sciences
Conclusions— In Chinese patients with atrial fibrillation, the benefits of warfarin therapy for stroke prevention and ICH risk are closely dependent on the quality of anticoagulation, as reflected by TTR. Even at the top TTR quartile, warfarin was associated with a higher stroke and ICH risk than dabigatran.
Source: Stroke - December 22, 2014 Category: Neurology Authors: Ho, C.-W., Ho, M.-H., Chan, P.-H., Hai, J.-J., Cheung, E., Yeung, C.-Y., Lau, K.-K., Chan, K.-H., Lau, C.-P., Lip, G. Y. H., Leung, G. K.-K., Tse, H.-F., Siu, C.-W. Tags: Coumarins, Other anticoagulants, Anticoagulants Clinical Sciences Source Type: research

Does Dabigatran Increase the Risk of Delayed Hematoma Expansion in a Rat Model of Collagenase-Induced Intracerebral Hemorrhage?
This study aims to clarify whether dabigatran increases the risk of delayed hematoma expansion in a rat ICH model.
Source: Journal of Stroke and Cerebrovascular Diseases - November 25, 2014 Category: Neurology Authors: Shunsuke Tanoue, Joji Inamasu, Masayuki Yamada, Hiroshi Toyama, Yuichi Hirose Source Type: research

Efficacy and Safety of Novel Oral Anticoagulants in Patients with Cervical Artery Dissections
We report on the use, safety, and efficacy of NOACs in the treatment of CAD. Methods: We retrospectively identified patients diagnosed with CAD at a single academic center between January 2010 and August 2013. Patients were categorized by their antithrombotic treatment at hospital discharge with a NOAC (dabigatran, rivaroxaban, or apixaban), traditional anticoagulant (AC: warfarin or treatment dose low-molecular weight heparin), or antiplatelet agent (AP: aspirin, clopidogrel, or aspirin/extended-release dypyridamole). Using appropriate tests, we compared the baseline medical history, presenting clinical symptoms and initi...
Source: Cerebrovascular Diseases - November 12, 2014 Category: Neurology Source Type: research

Correspondence Embolic strokes of undetermined source: support for a new clinical construct–Authors' reply
The interesting and important observations summarised by Pascal Gratz and colleagues lend support to the embolic strokes of undetermined source (ESUS) construct developed in our recent Personal View. Two large, international randomised trials are underway that will compare new oral anticoagulants (dabigatran and rivaroxaban, respectively) with aspirin for secondary stroke prevention in ESUS cohorts, and assess the therapeutic implications of this novel construct. Finally, cryptogenic (of unknown cause) stroke will be the subject of these long-overdue, randomised trials that will shed light on this obscure, but common, entity.
Source: Lancet Neurology - September 16, 2014 Category: Neurology Authors: Robert G Hart, Hans-Christoph Diener, Stuart J Connolly Tags: Correspondence Source Type: research

Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient
Novel oral anticoagulants (NOACs) are the recent therapeutic breakthrough in the thromboprophylaxis of non-valvular atrial fibrillation (NVAF). There are currently three different molecules approved for NVAF: dabigatran, rivaroxaban and apixaban. All three agents have demonstrated at least non-inferiority at major clinical endpoints compared to warfarin with their major advantage being the fixed-dose regimen that necessitates no regular blood tests and protects patients from the disastrous effects of infra-therapeutic (embolism) or supra-therapeutic (hemorrhage) anticoagulation.
Source: Journal of the Neurological Sciences - September 14, 2014 Category: Neurology Authors: Apostolos Safouris, Anne Demulder, Nikos Triantafyllou, Georgios Tsivgoulis Tags: Letter to the Editor Source Type: research

Cardioembolic stroke in a patient taking Dabigatran Etexilate: The first case report of clinical and pharmacologic resistance
Dabigatran Etexilate (DE) was the first oral direct thrombin inhibitor approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) [1,2]. One of its main advantages relies on predictable pharmacokinetics allowing a fixed dosage for each patient. In fact, although a range of pharmacokinetic response to DE has been demonstrated, up until now no case has been described of clinical and pharmacologic resistance.
Source: Journal of the Neurological Sciences - August 29, 2014 Category: Neurology Authors: João Sargento-Freitas, Fernando Silva, João Pego, Cristina Duque, Gustavo Cordeiro, Luís Cunha Tags: Letter to the Editor Source Type: research

Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin Clinical Sciences
Conclusions— In this sample of AF patients with ICB on oral anticoagulants, dabigatran was not associated with higher in-hospital mortality compared with warfarin. Hence, reluctance to use dabigatran because of a lack of approved reversal agents is not supported by our results.
Source: Stroke - July 28, 2014 Category: Neurology Authors: Alonso, A., Bengtson, L. G. S., MacLehose, R. F., Lutsey, P. L., Chen, L. Y., Lakshminarayan, K. Tags: Cerebrovascular disease/stroke, Coumarins, Other anticoagulants, Arrhythmias, clinical electrophysiology, drugs, Anticoagulants Clinical Sciences Source Type: research

New aspects of stroke medicine.
Abstract Systemic thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) remains the only effective and approved medical treatment of acute ischemic stroke. Several studies have demonstrated the importance of rapid recanalization. The efficacy of thrombectomy has so far not been sufficiently shown in randomized clinical trials; therefore, inclusion of suitable patients in one of the currently ongoing randomized trials is of great importance. The early treatment with magnesium after acute ischemic stroke during the pre-hospital phase did not prove to be neuroprotective. Intermittent pneumatic compr...
Source: Der Nervenarzt - June 28, 2014 Category: Neurology Authors: Diener HC, Frank B, Hajjar K, Weimar C Tags: Nervenarzt Source Type: research